Literature DB >> 22499670

CD98 at the crossroads of adaptive immunity and cancer.

Joseph M Cantor1, Mark H Ginsberg.   

Abstract

Adaptive immunity, a vertebrate specialization, adds memory and exquisite specificity to the basic innate immune responses present in invertebrates while conserving metabolic resources. In adaptive immunity, antigenic challenge requires extremely rapid proliferation of rare antigen-specific lymphocytes to produce large, clonally expanded effector populations that neutralize pathogens. Rapid proliferation and resulting clonal expansion are dependent on CD98, a protein whose well-conserved orthologs appear restricted to vertebrates. Thus, CD98 supports lymphocyte clonal expansion to enable protective adaptive immunity, an advantage that could account for the presence of CD98 in vertebrates. CD98 supports lymphocyte clonal expansion by amplifying integrin signals that enable proliferation and prevent apoptosis. These integrin-dependent signals can also provoke cancer development and invasion, anchorage-independence and the rapid proliferation of tumor cells. CD98 is highly expressed in many cancers and contributes to formation of tumors in experimental models. Strikingly, vertebrates, which possess highly conserved CD98 proteins, CD98-binding integrins and adaptive immunity, also display propensity towards invasive and metastatic tumors. In this Commentary, we review the roles of CD98 in lymphocyte biology and cancer. We suggest that the CD98 amplification of integrin signaling in adaptive immunity provides survival benefits to vertebrates, which, in turn, bear the price of increased susceptibility to cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499670      PMCID: PMC3336374          DOI: 10.1242/jcs.096040

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  126 in total

1.  Functional effects of a monoclonal antibody directed against a distinct epitope on 4F2 molecular complex in human peripheral blood mononuclear cell activation.

Authors:  G C Spagnoli; C Ausiello; C Palma; G Bellone; G Ippoliti; M Letarte; F Malavasi
Journal:  Cell Immunol       Date:  1991-08       Impact factor: 4.868

2.  Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx.

Authors:  F Esteban; F Ruiz-Cabello; A Concha; M Perez Ayala; M Delgado; F Garrido
Journal:  Cancer       Date:  1990-10-01       Impact factor: 6.860

3.  Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.

Authors:  D M Salter; A S Krajewski; T Sheehan; G Turner; R J Cuthbert; A Mclean
Journal:  J Pathol       Date:  1989-11       Impact factor: 7.996

4.  Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.

Authors:  H Holte; C de Lange Davies; K Beiske; T Stokke; P F Marton; E B Smeland; J Høie; S Kvaløy
Journal:  Int J Cancer       Date:  1989-12-15       Impact factor: 7.396

5.  A monoclonal antibody (H227) recognizing a new epitope of 4F2 molecular complex associated with T cell activation.

Authors:  M Nakao; K Kubo; A Hara; N Hirohashi; E Futagami; S Shichijo; K Sagawa; K Itoh
Journal:  Cell Immunol       Date:  1993-11       Impact factor: 4.868

6.  Stimulation of system y(+)-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes.

Authors:  J Bertran; S Magagnin; A Werner; D Markovich; J Biber; X Testar; A Zorzano; L C Kühn; M Palacin; H Murer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

7.  The human 4F2 antigen: evidence for cryptic and noncryptic epitopes and for a role of 4F2 in human T lymphocyte activation.

Authors:  A W Freidman; L A Diaz; S Moore; J Schaller; D A Fox
Journal:  Cell Immunol       Date:  1994-04-01       Impact factor: 4.868

8.  Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia.

Authors:  H Taskov; A Pashov; E ffmitrova; M Yordanova; M Serbinova
Journal:  Leuk Res       Date:  1996-01       Impact factor: 3.156

9.  CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells.

Authors:  A P Warren; K Patel; D J McConkey; R Palacios
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

Review 10.  A new family of proteins (rBAT and 4F2hc) involved in cationic and zwitterionic amino acid transport: a tale of two proteins in search of a transport function.

Authors:  M Palacín
Journal:  J Exp Biol       Date:  1994-11       Impact factor: 3.312

View more
  83 in total

1.  Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer.

Authors:  Kyoichi Kaira; Kazuhisa Arakawa; Kimihiro Shimizu; Noboru Oriuchi; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  CD98hc (SLC3A2) loss protects against ras-driven tumorigenesis by modulating integrin-mediated mechanotransduction.

Authors:  Soline Estrach; Sin-Ae Lee; Etienne Boulter; Sabrina Pisano; Aurélia Errante; Floriane S Tissot; Laurence Cailleteau; Catherine Pons; Mark H Ginsberg; Chloé C Féral
Journal:  Cancer Res       Date:  2014-09-29       Impact factor: 12.701

3.  Programmed death-1 controls T cell survival by regulating oxidative metabolism.

Authors:  Victor Tkachev; Stefanie Goodell; Anthony W Opipari; Ling-Yang Hao; Luigi Franchi; Gary D Glick; James L M Ferrara; Craig A Byersdorfer
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

4.  TRE17/USP6 regulates ubiquitylation and trafficking of cargo proteins that enter cells by clathrin-independent endocytosis.

Authors:  Yuji Funakoshi; Margaret M Chou; Yasunori Kanaho; Julie G Donaldson
Journal:  J Cell Sci       Date:  2014-09-01       Impact factor: 5.285

5.  Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice.

Authors:  Bo Xiao; Hamed Laroui; Emilie Viennois; Saravanan Ayyadurai; Moiz A Charania; Yuchen Zhang; Zhan Zhang; Mark T Baker; Benyue Zhang; Andrew T Gewirtz; Didier Merlin
Journal:  Gastroenterology       Date:  2014-02-04       Impact factor: 22.682

6.  Structural basis for amino acid exchange by a human heteromeric amino acid transporter.

Authors:  Di Wu; Tamara N Grund; Sonja Welsch; Deryck J Mills; Max Michel; Schara Safarian; Hartmut Michel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-17       Impact factor: 11.205

7.  Hook1, microtubules, and Rab22: mediators of selective sorting of clathrin-independent endocytic cargo proteins on endosomes.

Authors:  Lymarie Maldonado-Báez; Julie G Donaldson
Journal:  Bioarchitecture       Date:  2013-09-01

8.  Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc.

Authors:  Robert Fuchs; Anika Stracke; Viktoria Holzmann; Gerfried Luschin-Ebengreuth; Nathalie Meier-Allard; Nadine Ebner; Teresa Maria Lassacher; Markus Absenger-Novak; Eleonore Fröhlich; Matthias Schittmayer; Sara Cano Crespo; Manuel Palacin; Beate Rinner; Ruth Birner-Gruenberger
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-06-15       Impact factor: 4.739

9.  Ubiquitylation of CD98 limits cell proliferation and clonal expansion.

Authors:  Jailal N G Ablack; Patrick J Metz; John T Chang; Joseph M Cantor; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2015-10-22       Impact factor: 5.285

10.  Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.

Authors:  William R Wikoff; Samir Hanash; Brian DeFelice; Suzanne Miyamoto; Matt Barnett; Yang Zhao; Gary Goodman; Ziding Feng; David Gandara; Oliver Fiehn; Ayumu Taguchi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.